adrenal gland disease: A disease involving the adrenal gland.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
219 |
4. Check minimum number of eventsNone |
219 |
5. Include endpointsNone |
219 |
6. Filter based on genotype QC (FinnGen only) |
219 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E27
- Name in latin
- Alia hyperfunctio adrenocorticalis
Similar endpoints
↥List of similar endpoints to
Other adrenocortical overactivity
based on the number of shared cases.
Similar with more cases:
- Other disorders of adrenal gland
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4574 | 3566 | 1002 |
| Only index persons | 3335 | 2615 | 720 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.09 | 0.10 | 0.03 |
| Only index persons | 0.08 | 0.10 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 7.91 | 7.69 | 8.52 |
| Only index persons | 8.08 | 7.85 | 8.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 219 | 183 | 36 |
| Unadjusted period prevalence (%) | 0.05 | 0.06 | 0.02 |
| Median age at first event (years) | 14.57 | 8.40 | 45.90 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 191
- Matched controls
- 1911
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E27.0
ICD-10 Finland
Other adrenocortical overactivity
+∞
239.3
176
*
H02AB09
ATC
hydrocortisone; systemic
24.6
35.1
50
27
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
27.8
26
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
22.3
21
*
H02AA02
ATC
fludrocortisone; oral
+∞
22.3
21
*
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
13.1
18.6
33
30
E27.4
ICD-10 Finland
Other and unspecified adrenocortical insufficiency
+∞
15.8
15
*
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
173.6
15.7
16
*
E30.1
ICD-10 Finland
Precocious puberty
+∞
12.6
12
*
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
138.7
12.6
13
*
25508
ICD-8 Finland
Diseases of adrenal glands, Hyperfunctio adrenocorticalis alia
+∞
11.6
11
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
8.5
9.4
20
26
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
52.4
8.8
10
*
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
6.2
8.4
22
39
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
+∞
8.4
8
*
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
+∞
8.4
8
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
7.4
48
197
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
+∞
7.3
7
*
E34.45
ICD-10 Finland
Abnormal growth increase
+∞
7.3
7
*
Z51.80
ICD-10 Finland
Manipulation of puberty development with hormone therapy
+∞
7.3
7
*
E24.9
ICD-10 Finland
Cushing syndrome, unspecified
+∞
7.3
7
*
M05BA04
ATC
alendronic acid; oral
7.3
6.7
15
22
H02AB07
ATC
prednisone; oral
4.1
6.4
24
65
E27.2
ICD-10 Finland
Addisonian crisis
+∞
6.3
6
*
E24.8
ICD-10 Finland
Other Cushing syndrome
+∞
6.3
6
*
E66.01
ICD-10 Finland
Obesity due to excess calories
3.7
6.0
25
74
H03AA01
ATC
levothyroxine sodium; systemic
2.7
6.0
44
193
C03CA01
ATC
furosemide; systemic
3.2
6.0
31
109
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
39
101
4.48
14.23
2.3
1.6
10.5
7.3
u/l
0.53
21
66
41
111
4.31
14.13
2.0
1.5
15.6
15.7
iu/l
0.01
22
79
16
44
3.84
5.31
1.3
1.3
—
—
—
0
0
29
116
2.73
5.30
3.4
3.3
5.0
4.9
pmol/l
0.24
29
103
45
228
2.23
4.97
2.7
2.0
—
—
—
0
0
72
449
1.90
4.49
5.1
3.2
2.4
2.4
mmol/l
0.92
64
395
100
695
1.81
4.39
3.6
2.6
72.5
71.3
nmol/l
0.17
94
627
33
159
2.27
4.08
2.8
1.9
—
—
—
0
0
191
1651
2.23
3.93
6.1
4.2
1.9
1.8
mu/l
0.54
179
1536
32
156
2.23
3.85
2.8
1.9
—
—
—
0
0
101
729
1.72
3.73
11.4
8.2
1.2
1.2
mmol/l
0.18
88
647
21
89
2.50
3.44
11.9
2.6
1.2
1.2
mmol/l
0.98
21
80
14
48
3.05
3.36
1.6
1.4
—
—
—
0
0
14
48
3.05
3.36
1.6
1.4
—
—
—
0
0
72
486
1.72
3.32
1.9
1.6
91.1
95.4
pmol/l
0.35
39
245
6
7
8.77
3.28
2.3
1.0
75.5
74.1
%
—
6
7
6
7
8.77
3.28
2.3
1.0
478.8
284.6
mu/l
—
6
7
169
1432
1.79
3.24
5.8
3.7
14.3
14.3
pmol/l
0.06
153
1302
95
695
1.65
3.21
7.6
6.0
12.3
12.5
umol/l
0.02
88
647
15
56
2.80
3.13
1.7
1.2
—
—
—
0
0
15
58
2.70
2.94
1.7
1.2
—
—
—
0
0
11
36
3.16
2.85
1.5
1.3
—
—
—
0
0
8
18
4.57
2.82
1.9
2.1
—
—
—
0
0
92
688
1.58
2.74
11.4
7.8
1.2
1.2
mmol/l
0.68
87
641
8
20
4.11
2.59
2.0
1.8
—
—
—
0
0
58
394
1.64
2.54
3.0
2.5
—
—
—
0
0
132
1084
1.55
2.53
10.2
8.5
4.3
3.8
e9/l
1.67
116
920
34
199
1.84
2.50
8.4
6.9
1.9
0.8
mmol/l
1.64
26
151
8
21
3.91
2.49
1.9
1.9
—
—
—
0
0
56
379
1.64
2.48
3.4
3.1
34.9
26.3
ng/l
0.22
34
188
32
185
1.85
2.45
1.2
1.3
364.4
124.0
iu/ml
—
8
70
22
112
2.07
2.40
8.0
7.8
14.2
14.1
kpa
0.02
22
107
22
112
2.07
2.40
7.9
7.8
5.5
5.1
kpa
0.67
22
107
51
340
1.65
2.39
2.5
3.1
0.9
1.4
mg/l
0.58
34
236
6
13
4.71
2.28
1.3
2.0
—
—
—
0
0
6
13
4.71
2.28
1.3
2.0
—
—
—
0
0
6
13
4.71
2.28
1.3
2.0
—
—
—
0
0
162
1408
1.58
2.28
3.8
3.2
5.6
5.6
mmol/l
0.16
151
1287
132
1100
1.50
2.24
10.9
6.0
91.6
86.4
u/l
0.39
125
1022
81
613
1.51
2.19
4.8
3.4
—
—
—
0
0
9
30
3.08
2.17
2.0
1.8
—
—
—
0
0
23
124
1.96
2.17
1.3
1.3
288.7
293.6
miu/ml
—
10
60
18
89
2.11
2.13
3.0
1.7
—
—
—
0
0
14
280
0.47
2.09
1.6
1.5
—
—
—
0
0
38
243
1.68
2.08
3.8
4.2
885.6
765.2
ng/l
0.13
31
192
28
164
1.81
2.07
1.5
1.6
1346.0
1038.6
nmol/l
0.89
23
125
25
142
1.86
2.03
1.7
1.3
173.2
380.9
u/ml
0.63
25
134
9
32
2.89
2.02
1.8
1.3
—
—
—
0
0
70
522
1.50
2.01
5.0
3.3
0.3
0.3
e6/l
0.19
57
381
5
11
4.62
1.95
1.0
1.0
—
—
—
0
0
32
199
1.71
1.94
3.4
2.4
2.5
2.4
mmol/l
0.91
27
164
15
73
2.13
1.85
1.7
1.3
—
—
—
0
0
12
54
2.29
1.77
4.6
3.8
43.5
53.0
%
0.44
12
54
6
145
0.40
1.72
1.2
1.6
—
—
—
0
0
14
69
2.10
1.68
2.6
1.6
—
—
—
0
0
124
1056
1.40
1.67
3.2
3.0
37.8
30.9
u/l
0.75
119
1006
146
1284
1.41
1.60
3.4
3.1
1.3
1.2
mmol/l
1.41
139
1204
63
480
1.44
1.59
2.2
2.4
2.7
2.7
mg/l
0.11
58
412
137
1193
1.40
1.58
5.4
4.0
37.9
38.0
mmol/mol
0.04
131
1120
5
15
3.39
1.53
1.4
1.4
—
—
—
0
0
5
15
3.39
1.53
1.4
1.4
—
—
—
0
0
5
15
3.39
1.53
1.4
1.4
—
—
—
0
0
5
15
3.39
1.53
1.4
1.4
—
—
—
0
0
6
21
2.91
1.51
1.0
1.0
—
—
—
0
0
5
16
3.17
1.44
1.4
1.4
—
—
—
0
0
5
16
3.17
1.44
1.4
1.4
—
—
—
0
0
6
22
2.77
1.44
1.3
2.1
—
—
—
0
0
6
22
2.77
1.44
1.2
1.1
—
—
—
0
0
10
46
2.23
1.42
2.7
2.1
—
—
—
0
0
12
60
2.06
1.41
2.1
2.3
—
—
—
0
0
11
54
2.09
1.35
1.6
1.3
—
—
—
0
0
8
35
2.33
1.28
1.1
1.0
—
—
—
0
0
9
45
2.04
1.25
2.9
2.3
—
—
—
0
0
33
233
1.49
1.22
3.4
6.2
30.5
30.2
s
0.11
33
227
6
26
2.34
1.19
1.3
1.1
—
—
—
0
0
11
57
1.98
1.19
2.0
2.0
—
—
—
0
0
179
1664
1.41
1.17
22.1
13.4
13.6
13.3
%
2.02
172
1632
29
201
1.51
1.17
4.0
2.6
2.3
2.5
g/l
1.26
29
182
5
113
0.43
1.16
1.2
1.5
—
—
—
0
0
5
20
2.53
1.15
1.2
1.5
—
—
—
0
0
14
81
1.78
1.12
1.3
1.4
—
—
—
0
0
148
1344
1.31
1.08
3.7
3.2
1.4
1.5
mmol/l
0.92
141
1254
102
883
1.29
1.07
6.4
4.8
0.0
0.0
estimate
0.00
22
187
32
233
1.44
1.03
1.5
1.6
1.5
1.4
%
0.59
27
213
149
1360
1.30
1.01
3.9
3.3
4.4
4.6
mmol/l
1.10
143
1278
102
890
1.27
0.99
4.9
3.4
0.0
0.0
estimate
0.00
22
182
190
1799
1.42
0.98
20.1
10.7
21.1
22.3
mg/l
0.24
150
1327
149
1364
1.29
0.97
4.1
3.5
2.6
2.7
mmol/l
0.86
143
1269
48
595
0.75
0.96
2.1
2.4
—
—
—
0
0
37
281
1.38
0.95
5.4
4.0
14.3
16.3
mg/mmol
0.10
28
192
32
238
1.40
0.93
5.7
7.6
1.4
1.4
mmol/l
0.00
22
191
6
28
2.17
0.92
1.5
1.9
—
—
—
0
0
7
130
0.52
0.91
1.4
1.7
—
—
—
0
0
30
223
1.40
0.88
4.0
2.6
12.2
14.2
umol/l
0.70
30
210
101
890
1.25
0.87
4.9
3.3
0.0
0.0
estimate
0.00
22
180
79
677
1.26
0.87
1.6
1.7
0.9
2.9
u/ml
1.48
16
155
30
224
1.39
0.86
11.9
10.6
24.5
24.8
mmol/l
0.20
30
224
137
1253
1.25
0.84
5.0
3.7
12.5
8.9
mm/h
2.06
128
1148
15
97
1.59
0.84
1.3
1.5
—
—
—
0
0
146
1345
1.26
0.83
19.3
8.4
96.1
98.0
ml/min/173m2
0.34
120
1008
57
472
1.28
0.82
5.8
3.3
0.1
0.0
estimate
0.48
22
186
40
316
1.33
0.81
3.3
3.1
2.2
4.5
e6/l
1.26
21
161
13
82
1.62
0.80
1.7
2.8
68.0
85.8
ml/min/173m2
—
6
31
10
59
1.73
0.77
1.4
1.9
—
—
—
0
0
86
755
1.23
0.75
2.5
2.0
—
—
—
0
0
24
177
1.40
0.74
9.8
6.7
24.3
24.1
mmol/l
0.12
24
177
5
26
1.94
0.71
3.8
2.0
—
—
—
0
0
11
69
1.63
0.70
13.9
9.4
95.8
94.5
%
0.88
11
69
32
252
1.32
0.67
2.7
2.3
3707.3
6002.0
u/l
0.25
12
98
7
43
1.65
0.67
1.7
1.9
—
—
—
0
0
74
653
1.20
0.60
5.2
3.3
—
—
—
0
0
54
625
0.82
0.59
2.5
2.6
—
—
—
0
0
6
35
1.73
0.58
4.0
1.9
—
—
—
0
0
39
324
1.25
0.56
3.2
3.0
1.1
1.0
e6/l
0.07
20
168
6
37
1.64
0.56
1.3
1.3
—
—
—
0
0
13
93
1.42
0.49
1.2
1.8
—
—
—
0
0
29
238
1.25
0.47
3.8
2.9
171.8
272.5
ng/l
0.27
16
133
31
257
1.24
0.46
1.3
1.2
1.4
9.7
u/ml
—
8
105
47
409
1.19
0.44
3.8
3.1
1.0
1.0
kg/l
0.77
12
57
15
113
1.35
0.44
3.2
2.5
—
—
—
0
0
13
96
1.38
0.42
13.1
13.3
1.2
1.1
mg/l
0.39
13
89
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
34
396
0.83
0.40
1.6
1.5
—
—
—
0
0
0
18
0.00
0.40
0.0
3.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
22
179
1.25
0.39
1.8
1.3
—
—
—
0
0
86
794
1.14
0.38
4.5
4.0
—
—
—
0
0
9
69
1.32
0.37
1.3
1.5
—
—
—
0
0
14
178
0.77
0.36
1.6
1.4
—
—
—
0
0
39
442
0.86
0.34
2.4
2.1
—
—
—
0
0
12
91
1.34
0.34
1.6
1.6
—
—
—
0
0
6
47
1.28
0.32
1.2
2.0
—
—
—
0
0
7
54
1.31
0.30
3.0
2.5
0.6
0.5
nmol/l
—
7
45
33
373
0.86
0.29
2.2
1.9
—
—
—
0
0
10
76
1.33
0.28
1.5
1.7
—
—
—
0
0
10
78
1.30
0.24
1.5
1.7
—
105.7
—
0
7
29
257
1.15
0.23
1.3
1.2
52.9
19.9
iu/ml
—
7
67
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
1.0
—
0
8
23
206
1.13
0.16
1.0
1.1
—
—
—
0
0
13
151
0.85
0.16
1.5
1.6
—
—
—
0
0
8
73
1.10
0.16
1.0
1.2
—
—
—
0
0
11
94
1.18
0.13
1.1
1.2
—
—
—
0
0
181
1785
1.08
0.13
20.8
12.3
39.3
39.2
%
0.09
155
1506
11
127
0.86
0.13
1.5
1.4
—
—
—
0
0
11
127
0.86
0.13
1.5
1.4
—
—
—
0
0
11
127
0.86
0.13
1.5
1.4
—
—
—
0
0
11
127
0.86
0.13
1.5
1.4
—
—
—
0
0
5
47
1.07
0.09
1.2
1.1
—
—
—
0
0
9
85
1.06
0.07
1.2
1.4
—
—
—
0
0
17
158
1.08
0.06
6.4
5.2
5.2
1.9
ug/l
0.53
17
136
12
131
0.91
0.06
6.6
4.9
—
—
—
0
0
11
120
0.91
0.05
4.7
5.1
27.2
22.5
%
—
6
61
167
1672
0.99
0.00
4.7
4.0
—
—
—
0
0
20
202
0.99
0.00
2.1
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
8
79
1.01
0.00
1.0
1.1
—
10.3
—
0
16
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
17
170
1.00
0.00
1.1
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_ADREACT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ADREACT | 4.569 [3.1, 6.73] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.084 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 2952 females with E4_ADREACT died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have E4_ADREACT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.47% | No data |
| 5 | 2.272% | No data |
| 10 | 5.762% | No data |
| 15 | 11.548% | No data |
| 20 | 18.618% | No data |
Relationships between endpoints
↥Index endpoint: E4_ADREACT – Other adrenocortical overactivity
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data